- Home
- WLY vs NVCR Comparison
WLY vs NVCR Comparison
Compare WLY & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WLY | NVCR |
|---|---|---|
| Founded | 1807 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Books | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.3B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | WLY | NVCR |
|---|---|---|
| Price | $30.49 | $13.46 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $28.42 |
| AVG Volume (30 Days) | 675.4K | ★ 1.7M |
| Earning Date | 12-04-2025 | 10-30-2025 |
| Dividend Yield | ★ 4.48% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.87 | N/A |
| Revenue | ★ $1,665,756,000.00 | $642,269,000.00 |
| Revenue This Year | $0.86 | $9.75 |
| Revenue Next Year | $2.66 | $5.62 |
| P/E Ratio | $16.96 | ★ N/A |
| Revenue Growth | N/A | ★ 11.17 |
| 52 Week Low | $29.93 | $10.70 |
| 52 Week High | $47.26 | $34.13 |
Technical Indicators
Market Signals| Indicator | WLY | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 30.41 | 62.09 |
| Support Level | $29.93 | $10.79 |
| Resistance Level | $33.05 | $13.94 |
| Average True Range (ATR) | 1.73 | 0.61 |
| MACD | -0.45 | 0.23 |
| Stochastic Oscillator | 3.21 | 84.76 |
Price Performance
Historical ComparisonAbout WLY John Wiley & Sons Inc.
John Wiley & Sons Inc is one of the world's greatest publishers and a trusted leader in research and learning. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.